TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·November 4, 2026

United Therapeutics Corporation (UTHR) gains after earnings misses

United Therapeutics Corporation (UTHR) gains 0.3% even as earnings miss expectations, with investors weighing the latest results against the company’s outlook and pipeline progress.

Earnings FlashUTHRHealthcareBiotechnology
By TickerSpark·November 4, 2026·1 min read
United Therapeutics Corporation (UTHR) gains after earnings misses
▌Key Takeaway
United Therapeutics Corporation (UTHR) reported mixed earnings, missing EPS at $5.71 versus $6.01 expected but beating revenue at $0.83 billion versus $0.78 billion. Shares still gained 0.34% to $603.36, suggesting investors are giving more weight to the sales beat than the profit miss, though margin execution remains the key issue going forward.

United Therapeutics Corporation (UTHR) gains after earnings miss

United Therapeutics Corporation (UTHR) missed EPS estimates at $5.71 versus $6.01 but beat revenue estimates at $0.83B versus $0.78B, while shares gained 0.34% to $603.36 in regular-session trading.

Key Numbers

  • EPS: $5.71 actual versus $6.01 estimated, a miss.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $0.83B actual versus $0.78B estimated, a beat.
  • Stock reaction: UTHR closed at $603.36, up 0.34% from $601.32.
  • Regular-session range: $580.00 to $603.36.
  • Volume: 172,151 shares versus a 717,282 average.
  • Revenue Beat, Profit Miss Creates a Mixed Signal

    The result cleared the sales hurdle but missed the profit hurdle. Revenue reached $0.83B against a $0.78B estimate, while EPS came in at $5.71 against $6.01.

    Price action was measured. UTHR ended regular-session trading at $603.36 after touching $580.00. Volume was below the 717,282 average, limiting evidence of a heavy repricing.

    The recent EPS record adds caution. UTHR beat estimates in February and August, then missed in May and November. The earnings call should center on why revenue beat while EPS missed, and whether that gap changes the profit outlook.

    Get AI research on any stock

    Instant reports, daily intelligence, and an AI analyst in your pocket.

    Get Started →

    Bottom Line

    UTHR's revenue beat and modest stock gain keep the story constructive, but the EPS miss makes profit execution the immediate test.

    Read the full UTHR research report
    ▌Common Questions

    Frequently asked questions

    +Did United Therapeutics (UTHR) beat or miss earnings?
    United Therapeutics missed earnings per share, reporting $5.71 versus the $6.01 estimate. It did beat revenue expectations, posting $0.83 billion in sales versus $0.78 billion expected.
    +Why did UTHR stock rise after missing EPS?
    UTHR rose because investors appeared to focus on the revenue beat and the company’s ability to top sales estimates. The stock closed at $603.36, up 0.34%, even though EPS came in below consensus.
    +What were United Therapeutics' key earnings numbers?
    United Therapeutics reported EPS of $5.71 against a $6.01 estimate and revenue of $0.83 billion against a $0.78 billion estimate. The stock traded between $580.00 and $603.36 during the session and finished at $603.36.
    +What does this earnings report mean for UTHR investors?
    The report is constructive on revenue but raises questions about profit execution and margins. Investors will likely watch the next earnings call for management’s explanation of the EPS miss and whether the company can sustain revenue growth without further pressure on profitability.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on UTHR?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the UTHR report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full UTHR research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the UTHR report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Creates a free TickerSpark account — newsletter included.

    or with email

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on UTHR

    More to read

    All articles
    United Therapeutics (UTHR): Tyvaso Growth Meets Pipeline Catalysts
    UTHR

    United Therapeutics (UTHR): Tyvaso Growth Meets Pipeline Catalysts

    United Therapeutics combines a cash-rich balance sheet with record Tyvaso sales and multiple late-stage catalysts, but concentration in its flagship franchise keeps execution risk elevated. The stock looks fairly valued for a high-quality specialty biopharma with meaningful upside tied to 2027 regulatory decisions.

    Nov 7·19 min
    United Therapeutics Corporation (UTHR) gains on deep earnings analysis
    UTHR

    United Therapeutics Corporation (UTHR) gains on deep earnings analysis

    United Therapeutics Corporation (UTHR) posted a mixed quarter, missing EPS but beating revenue as shares gained on the session. This deep-dive looks beyond the headline, examining record Tyvaso sales, the Liquidia settlement, margin pressure, pipeline breadth, and why investors focused on growth over the earnings miss.

    Nov 4·7 min
    United Therapeutics Corporation (UTHR) rises on patent win
    UTHR

    United Therapeutics Corporation (UTHR) rises on patent win

    United Therapeutics Corporation (UTHR) rises after a Delaware court found Liquidia infringed two patent claims tied to inhaled treprostinil for PH-ILD. The ruling strengthens Tyvaso’s competitive position, while strong recent earnings and analyst support add to the bullish tone.

    Oct 1·6 min